Mental Health

Mobilize Recovery Cross-Country Bus Tour Galvanizes Community, Prevents Overdoses

Fifteen cities to host events in partnership with iHeartMedia, Meta, SAMHSA, Inseparable, and dozens of community partners coinciding with nationwide…

8 months ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company’s In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management…

8 months ago

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE…

8 months ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that…

8 months ago

BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates

Company Announces 11th Recent System Installed in Israel, with More Expected this YearBURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE…

8 months ago

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind”…

8 months ago

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe…

8 months ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care

Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription productOral mucositis, also called "chemo…

8 months ago

Lender Requests to Convert Loan to MindBio Shares

VANCOUVER, BC / ACCESSWIRE / April 16, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio") is pleased to…

8 months ago